\_\_\_\_\_\_

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)

217-9197 (toll free).

Reviewer: markspencer

Timestamp: [year=2009; month=1; day=22; hr=9; min=18; sec=49; ms=674; ]

\_\_\_\_\_\_

## Validated By CRFValidator v 1.0.3

Application No: 10551405 Version No: 2.0

Input Set:

Output Set:

**Started:** 2009-01-08 17:36:10.597

Finished: 2009-01-08 17:36:39.094

**Elapsed:** 0 hr(s) 0 min(s) 28 sec(s) 497 ms

Total Warnings: 23

Total Errors: 12

No. of SeqIDs Defined: 23

Actual SeqID Count: 23

Error code		Error Description	
W	213	Artificial or Unknown found in <213> in SEQ ID (3	.)
E	257	Invalid sequence data feature in <221> in SEQ ID	(1)
W	213	Artificial or Unknown found in <213> in SEQ ID (2	2)
W	213	Artificial or Unknown found in $\langle 213 \rangle$ in SEQ ID (3	3)
W	213	Artificial or Unknown found in <213> in SEQ ID (4	ł)
Ε	257	Invalid sequence data feature in <221> in SEQ ID	(4)
Ε	257	Invalid sequence data feature in <221> in SEQ ID	(4)
Ε	257	Invalid sequence data feature in <221> in SEQ ID	(4)
W	213	Artificial or Unknown found in <213> in SEQ ID (5	5)
E	257	Invalid sequence data feature in <221> in SEQ ID	(5)
Ε	257	Invalid sequence data feature in <221> in SEQ ID	(5)
W	213	Artificial or Unknown found in <213> in SEQ ID (6	5)
Ε	257	Invalid sequence data feature in <221> in SEQ ID	(6)
Ε	257	Invalid sequence data feature in <221> in SEQ ID	(6)
W	213	Artificial or Unknown found in <213> in SEQ ID (	7)
W	213	Artificial or Unknown found in <213> in SEQ ID (8	3)
W	213	Artificial or Unknown found in <213> in SEQ ID (9	9)
W	213	Artificial or Unknown found in <213> in SEQ ID (3	0)
W	213	Artificial or Unknown found in <213> in SEQ ID (3	1)
Ε	257	Invalid sequence data feature in $\langle 221 \rangle$ in SEQ ID	(11)

## Input Set:

## Output Set:

**Started:** 2009-01-08 17:36:10.597

Finished: 2009-01-08 17:36:39.094

**Elapsed:** 0 hr(s) 0 min(s) 28 sec(s) 497 ms

Total Warnings: 23
Total Errors: 12

No. of SeqIDs Defined: 23

Actual SeqID Count: 23

Error code		Error Description
W	213	Artificial or Unknown found in <213> in SEQ ID (12)
W	213	Artificial or Unknown found in <213> in SEQ ID (13)
W	213	Artificial or Unknown found in <213> in SEQ ID (14)
W	213	Artificial or Unknown found in <213> in SEQ ID (15)
W	213	Artificial or Unknown found in <213> in SEQ ID (16)
W	213	Artificial or Unknown found in <213> in SEQ ID (17)
W	213	Artificial or Unknown found in <213> in SEQ ID (18)
W	213	Artificial or Unknown found in <213> in SEQ ID (19)
W	213	Artificial or Unknown found in <213> in SEQ ID (20) This error has occured more than 20 times, will not be displayed
Ε	257	Invalid sequence data feature in <221> in SEQ ID (23)
E	257	Invalid sequence data feature in <221> in SEQ ID (23)
Ε	257	Invalid sequence data feature in <221> in SEQ ID (23)

## SEQUENCE LISTING

```
<110> Berzofsky, Jay A.
      Okazaki, Takahiro
<120> Enhanced HIV-1 Vaccines and Methods for Their Use
<130> 015280-481100US
<140> 10551405
<141> 2009-01-08
<150> US 60/459,507
<151> 2003-03-31
<150> WO PCT/US04/09617
<151> 2004-03-29
<160> 23
<170> PatentIn Ver. 2.1
<210> 1
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:variant of
      synthetic sequence motif derived from {\tt HIV-1}
      reverse transcriptase (RT) catalytic site region,
      immunostimulating peptide
<220>
<221> MOD_RES
<222> (1)
<223> Xaa = any hydrophobic amino acid
<400> 1
Xaa Leu Tyr Gln Tyr Met Asp Asp Val
 1
<210> 2
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:variant of
      synthetic sequence motif derived from {\tt HIV-1}
      reverse transcriptase (RT) catalytic site region,
      immunostimulating peptide, RT-2L9V, 2L9V
<400> 2
Val Leu Tyr Gln Tyr Met Asp Asp Val
```

```
1
```

```
<210> 3
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:variant of
     \verb|synthetic| sequence| motif| derived from HIV-1|
    reverse transcriptase (RT) catalytic site region,
     immunostimulating peptide, RT-1Y2L9V
<400> 3
Tyr Leu Tyr Gln Tyr Met Asp Asp Val
<210> 4
<211> 409
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:variant of
     \verb|synthetic| sequence| motif| derived from HIV-1|
     reverse transcriptase (RT) catalytic site region,
    immunostimulating peptide
<220>
<221> MOD_RES
<222> (1)..(200)
<223> Xaa = any amino acid, may be present or absent
<220>
<221> MOD_RES
<222> (201)
<223> Xaa = any hydrophobic amino acid
<220>
<221> MOD_RES
<222> (210)..(409)
<223> Xaa = any amino acid, may be present or absent
<400> 4
1.0
20
                            25
```

45

40

Xaa 65	Xaa	Xaa	Xaa	Xaa	Xaa 70	Xaa	Xaa	Xaa	Xaa	Xaa 75	Xaa	Xaa	Xaa	Xaa	Xaa 80
Xaa	Xaa	Xaa	Xaa	Xaa 85	Xaa	Xaa	Xaa	Xaa	Xaa 90	Xaa	Xaa	Xaa	Xaa	Xaa 95	Xaa
Xaa	Xaa	Xaa	Xaa 100	Xaa	Xaa	Xaa	Xaa	Хаа 105	Xaa	Xaa	Xaa	Xaa	Хаа 110	Xaa	Xaa
Xaa	Xaa	Хаа 115	Xaa	Xaa	Xaa	Xaa	Xaa 120	Xaa	Xaa	Xaa	Xaa	Хаа 125	Xaa	Xaa	Xaa
Xaa	Хаа 130	Xaa	Xaa	Xaa	Xaa	Хаа 135	Xaa	Xaa	Xaa	Xaa	Хаа 140	Xaa	Xaa	Xaa	Xaa
Хаа 145	Xaa	Xaa	Xaa	Xaa	Хаа 150	Xaa	Xaa	Xaa	Xaa	Хаа 155	Xaa	Xaa	Xaa	Xaa	Xaa 160
Xaa	Xaa	Xaa	Xaa	Хаа 165	Xaa	Xaa	Xaa	Xaa	Хаа 170	Xaa	Xaa	Xaa	Xaa	Хаа 175	Xaa
Xaa	Xaa	Xaa	Хаа 180	Xaa	Xaa	Xaa	Xaa	Хаа 185	Xaa	Xaa	Xaa	Xaa	Xaa 190	Xaa	Xaa
Xaa	Xaa	Хаа 195	Xaa	Xaa	Xaa	Xaa	Xaa 200	Xaa	Leu	Tyr	Gln	Tyr 205	Met	Asp	Asp
Val	Xaa 210	Xaa	Xaa	Xaa	Xaa	Xaa 215	Xaa	Xaa	Xaa	Xaa	Xaa 220	Xaa	Xaa	Xaa	Xaa
Xaa 225	Xaa	Xaa	Xaa	Xaa	Xaa 230	Xaa	Xaa	Xaa	Xaa	Xaa 235	Xaa	Xaa	Xaa	Xaa	Xaa 240
Xaa	Xaa	Xaa	Xaa	Xaa 245	Xaa	Xaa	Xaa	Xaa	Xaa 250		Xaa	Xaa	Xaa	Xaa 255	Xaa
Xaa	Xaa	Xaa	Xaa 260	Xaa	Xaa	Xaa	Xaa	Xaa 265	Xaa	Xaa	Xaa	Xaa	Xaa 270	Xaa	Xaa
Xaa	Xaa	Хаа 275	Xaa	Xaa	Xaa	Xaa	Xaa 280	Xaa	Xaa	Xaa	Xaa	Xaa 285	Xaa	Xaa	Xaa
Xaa	Хаа 290	Xaa	Xaa	Xaa	Xaa	Хаа 295	Xaa	Xaa	Xaa	Xaa	Xaa 300	Xaa	Xaa	Xaa	Xaa
Xaa 305	Xaa	Xaa	Xaa	Xaa	Xaa 310	Xaa	Xaa	Xaa	Xaa	Хаа 315	Xaa	Xaa	Xaa	Xaa	Xaa 320
Xaa	Xaa	Xaa	Xaa	Xaa 325	Xaa	Xaa	Xaa	Xaa	Xaa 330	Xaa	Xaa	Xaa	Xaa	Хаа 335	Xaa
Xaa	Xaa	Xaa	Xaa 340	Xaa	Xaa	Xaa	Xaa	Xaa 345	Xaa	Xaa	Xaa	Xaa	Хаа 350	Xaa	Xaa
Xaa															

370 375 390 385 395 400 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 405 <210> 5 <211> 409 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:variant of synthetic sequence motif derived from HIV-1 reverse transcriptase (RT) catalytic site region, immunostimulating peptide <220> <221> MOD\_RES <222> (1)..(200) <223> Xaa = any amino acid, may be present or absent <220> <221> MOD\_RES <222> (210)..(409) <223> Xaa = any amino acid, may be present or absent <400> 5 

Xaa	Хаа 130	Xaa	Xaa	Xaa	Xaa	Хаа 135	Xaa	Xaa	Xaa	Xaa	Xaa 140	Xaa	Xaa	Xaa	Xaa
Xaa 145	Xaa	Xaa	Xaa	Xaa	Xaa 150	Xaa	Xaa	Xaa	Xaa	Хаа 155	Xaa	Xaa	Xaa	Xaa	Xaa 160
Xaa	Xaa	Xaa	Xaa	Xaa 165	Xaa	Xaa	Xaa	Xaa	Хаа 170	Xaa	Xaa	Xaa	Xaa	Хаа 175	Xaa
Xaa	Xaa	Xaa	Хаа 180	Xaa	Xaa	Xaa	Xaa	Хаа 185	Xaa	Xaa	Xaa	Xaa	Хаа 190	Xaa	Xaa
Xaa	Xaa	Хаа 195	Xaa	Xaa	Xaa	Xaa	Xaa 200	Val	Leu	Tyr	Gln	Tyr 205	Met	Asp	Asp
Val	Хаа 210	Xaa	Xaa	Xaa	Xaa	Хаа 215	Xaa	Xaa	Xaa	Xaa	Xaa 220	Xaa	Xaa	Xaa	Xaa
Xaa 225	Xaa	Xaa	Xaa	Xaa	Xaa 230	Xaa	Xaa	Xaa	Xaa	Xaa 235	Xaa	Xaa	Xaa	Xaa	Xaa 240
Xaa	Xaa	Xaa	Xaa	Хаа 245	Xaa	Xaa	Xaa	Xaa	Хаа 250	Xaa	Xaa	Xaa	Xaa	Хаа 255	Xaa
Xaa	Xaa	Xaa	Xaa 260	Xaa	Xaa	Xaa	Xaa	Xaa 265	Xaa	Xaa	Xaa	Xaa	Хаа 270	Xaa	Xaa
Xaa	Xaa	Xaa 275	Xaa	Xaa	Xaa	Xaa	Xaa 280	Xaa	Xaa	Xaa	Xaa	Xaa 285	Xaa	Xaa	Xaa
Xaa	Xaa 290	Xaa	Xaa	Xaa	Xaa	Xaa 295	Xaa	Xaa	Xaa	Xaa	Xaa 300	Xaa	Xaa	Xaa	Xaa
Xaa 305	Xaa	Xaa	Xaa	Xaa	Хаа 310	Xaa	Xaa	Xaa	Xaa	Хаа 315	Xaa	Xaa	Xaa	Xaa	Xaa 320
Xaa	Xaa	Xaa	Xaa	Хаа 325	Xaa	Xaa	Xaa	Xaa	Хаа 330	Xaa	Xaa	Xaa	Xaa	Хаа 335	Xaa
Xaa	Xaa	Xaa	Хаа 340	Xaa	Xaa	Xaa	Xaa	Хаа 345	Xaa	Xaa	Xaa	Xaa	Хаа 350	Xaa	Xaa
Xaa	Xaa	Хаа 355	Xaa	Xaa	Xaa	Xaa	Хаа 360	Xaa	Xaa	Xaa	Xaa	Хаа 365	Xaa	Xaa	Xaa
Xaa	Хаа 370	Xaa	Xaa	Xaa	Xaa	Хаа 375	Xaa	Xaa	Xaa	Xaa	Xaa 380	Xaa	Xaa	Xaa	Xaa
Xaa 385	Xaa	Xaa	Xaa	Xaa	Xaa 390	Xaa	Xaa	Xaa	Xaa	Xaa 395	Xaa	Xaa	Xaa	Xaa	Xaa 400
Xaa	Xaa	Xaa	Xaa	Xaa 405	Xaa	Xaa	Xaa	Xaa							

<212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence:variant of synthetic sequence motif derived from  ${\tt HIV-1}$ reverse transcriptase (RT) catalytic site region, immunostimulating peptide <220> <221> MOD\_RES <222> (1)..(200) <223> Xaa = any amino acid, may be present or absent <220> <221> MOD\_RES <222> (210)..(409) <223> Xaa = any amino acid, may be present or absent <400> 6 

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Leu Tyr Gln Tyr Met Asp Asp

195 200 205

ValXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaa210215220

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 405

<210> 7

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:HIV-1 reverse transcriptase (RT) catalytic site region sequence motif, wild-type RT (179-187), RT-WT

<400> 7

Val Ile Tyr Gln Tyr Met Asp Asp Leu

```
<210> 8
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:variant of
      \verb|synthetic| sequence| motif| derived from HIV-1|
      reverse transcriptase (RT) catalytic site region,
      RT-1Y immunostimulating peptide
<400> 8
Tyr Ile Tyr Gln Tyr Met Asp Asp Leu
<210> 9
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:HIV-gag
      peptide, gag (p17) (77-85), p17-WT
<400> 9
Ser Leu Tyr Asn Thr Val Ala Thr Leu
<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Flu matrix
      peptide 58-66, FMP, Flu-MP (58-66)
<400> 10
Gly Ile Leu Gly Phe Val Phe Thr Leu
 1
                  5
<210> 11
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:variant of
      synthetic sequence motif derived from {\tt HIV-1}
      reverse transcriptase (RT) catalytic site region
      immunostimulating peptide
<220>
```

<221> MOD\_RES

```
<222> (1)
<223> Xaa = any hydrophobic amino acid, preferably Val
Xaa Leu Tyr Gln Tyr Met Asp Asp Val
<210> 12
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: RT (179-187) - WT
      alanine substituted peptide 1A
<400> 12
Ala Ile Tyr Gln Tyr Met Asp Asp Leu
<210> 13
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:RT (179-187)-WT
      alanine substituted peptide 2A
<400> 13
Val Ala Tyr Gln Tyr Met Asp Asp Leu
 1
<210> 14
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:RT (179-187)-WT
      alanine substituted peptide 3A
<400> 14
Val Ile Ala Gln Tyr Met Asp Asp Leu
<210> 15
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: RT (179-187)-WT
```

```
<400> 15
Val Ile Tyr Ala Tyr Met Asp Asp Leu
<210> 16
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:RT (179-187)-WT
      alanine substituted peptide 5A
<400> 16
Val Ile Tyr Gln Ala Met Asp Asp Leu
<210> 17
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: RT (179-187) - WT
      alanine substituted peptide 6A
<400> 17
Val Ile Tyr Gln Tyr Ala Asp Asp Leu
<210> 18
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: RT (179-187) - WT
      alanine substituted peptide 7A
<400> 18
Val Ile Tyr Gln Tyr Met Ala Asp Leu
 1
<210> 19
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: RT (179-187)-WT
      alanine substituted peptide 8A
```